What Happened to Paradigm Peptides? Federal Closure Timeline
Paradigm Peptides closed following a federal criminal case in the U.S. District Court for the Northern District of Indiana. The owners, Matthew Kawa and Jennifer Stechkober, pleaded guilty on December 10, 2025. Matthew Kawa was sentenced on March 24, 2026. Below is a DOJ-sourced timeline of the closure.
The closure event
The Paradigm Peptides website now displays a closure notice. According to the U.S. Department of Justice press release issued by the U.S. Attorney's Office for the Northern District of Indiana, the company's owners — Matthew Kawa and Jennifer Stechkober — pleaded guilty to federal charges on December 10, 2025. Matthew Kawa was sentenced approximately fifteen weeks later, on March 24, 2026.
For the official source of these facts and the full case caption, see the U.S. Department of Justice press release (Northern District of Indiana). This page cites only DOJ-published facts and does not speculate beyond what the Department of Justice has stated.
Federal case timeline
The DOJ-published timeline of the Paradigm Peptides matter, summarized in chronological order:
- December 10, 2025. Matthew Kawa and Jennifer Stechkober pleaded guilty to federal charges in the U.S. District Court for the Northern District of Indiana. The case was prosecuted by the U.S. Attorney's Office for the Northern District of Indiana.
- December 2025 onward. The Paradigm Peptides website transitioned to a closure notice. Pending order processing and customer communications stopped following the guilty pleas.
- March 24, 2026. Matthew Kawa was sentenced, per the DOJ release for the Northern District of Indiana.
Why the owners cannot return
A federal guilty plea in a case of this nature carries criminal disposition consequences that include enjoining the convicted parties from continuing to operate in the same product category. Pure U.S. Peptides is not party to the case and does not provide legal interpretation, but the practical effect of a federal criminal disposition is that the individuals named in the DOJ release cannot lawfully return to the business they were operating prior to the December 10, 2025 plea.
For researchers who relied on Paradigm Peptides for routine research-supply purchases, this means there is no path by which the original Paradigm Peptides operation returns under the same ownership. Any site claiming to be Paradigm Peptides under a new domain should be treated with significant caution. There is no public DOJ filing indicating an authorized relaunch of Paradigm Peptides under any name.
What this means for the broader research-supply market
The Paradigm Peptides closure removes a familiar name from the U.S. research-peptide shortlist. Independent research-volume estimates put residual brand-search interest in the tens of thousands of monthly queries. For an audience of independent researchers, the practical effect is a need to identify a U.S.-based replacement vendor that operates transparently within research-only positioning.
The cleaner the next vendor's positioning, the lower the risk of being put through another disruption like this one. Researchers comparing replacements typically check three things: whether the vendor publishes per-batch HPLC certificates of analysis, whether fulfillment is U.S.-based, and whether the catalog stays inside research-only scope rather than drifting into product categories that attract heightened regulatory scrutiny.
For a longer answer-style explainer of the closure facts, see our companion page Paradigm Peptides Shut Down — Where Researchers Are Going Now. If you're looking for a research-only U.S. supplier as a direct alternative, see our Paradigm Peptides alternative page.